

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-127)                                  CONCIZUMAB  
PRONUNCIATION                                  kon siz' ue mab  
THERAPEUTIC CLAIM                              Prevention of bleeding episodes in hemophilia A  
and B  
CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human proteinase inhibitor TFPI) (human-*Mus musculus* monoclonal mAB2021 heavy chain), disulfide with human-*Mus musculus* monoclonal mAB2021 κ-chain, dimer
2. Immunoglobulin G4-kappa, anti-(*Homo sapiens* Tissue factor pathway inhibitor (Lipoprotein-associated coagulation inhibitor, TFPI)); humanized monoclonal antibody; γ4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-21\*01 (86%) –(IGHD)-IGHJ6\*01 (93%)) [8.8.14] (1-121) -*Homo sapiens* IGHG4\*01 {hinge[S<sup>10</sup>>P(229)]} (122-448)] (135-219')-disulfide with κ light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29\*02 (90%) –IGKJ4\*01)[11.3.9] (1'-112') -*Homo sapiens* IGKC\*01 (113'-219')], dimer (227-227':230-230')-bisdisulfide

## STRUCTURAL FORMULA

### Heavy chain

EVQLVESGGG	LVKPGGSLRL	SCAASGFTFS	NYAMSWVRQT	PEKRLEWVAT	50
ISRSGSYSYF	PDSVQGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCARLG	100
GYDEGDAMDS	WGQGTIVTVS	SASTKGPSVF	PLAPCSRSTS	ESTAALGCLV	150
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSV	TVPSSSLGTK	200
TYTCNVDHKP	SNTKVDKRVE	SKYGPCCPPC	PAPEFLGGPS	VFLFPPKPKD	250
TLMISRTPPEV	TCVVVDVSQE	DPEVQFNWYV	DGVEVHNAKT	KPREEQFNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKGLP	SSIEKTIISKA	KGQPREPQVY	350
TLPPSQEEMT	KNQVSLTCLV	KGFYPVDIAV	EWESNGQPEN	NYKTTTPVLD	400
SDGSFFLYSR	LTVDKSRWQE	GNVFSQSVMH	EALHNHYTQK	SLSLSLGK	448

### Light chain

DIVMTQTPLS	LSVTPGQPAS	ISCKSSQSLL	ESDGKTYLW	YLQKPGQSPQ	50'
LLIYLVSILD	SGVPDRFSGS	GSRTDFTLKI	SRVEAEDVGV	YYCLQATHFP	100'
QTFGGGTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPPREK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDYSTSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

### Disulfide bridges location\*

22-96	22"-96"	23'-93'	23'''-93'''	135-219'	135"-219"	139'-199'	139'''-199'''
148-204	148"-204"	227-227"	230-230"	262-322	262"-322"	368-426	368"-426"

### Glycosylation sites (N)

Asn-298    Asn-298"

\* concizumab consists of two identical heavy chains of which one is unmarked and the other is marked with " and two identical light chains marked with ' and ""', respectively

MOLECULAR FORMULA                                  C<sub>6462</sub>H<sub>10004</sub>N<sub>1712</sub>O<sub>2046</sub>S<sub>46</sub> (non-glycosylated)

MOLECULAR WEIGHT	145.89 kDa
TRADEMARK	None
SPONSOR	Novo Nordisk
CODE DESIGNATIONS	NNC 0172-0000-2021, Anti-TFPI, mAb2021, NN7415
<u>CAS</u> REGISTRY NUMBER	1312299-39-0
UNII	68603V9EAF
WHO NUMBER	9636

gbk